Expertise in
16
conditions

Dr. Everett H. Meyer

Hematology
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 
Offers Telehealth
18 Years of Experience
Expertise in
16
conditions
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 

Overview

Everett Meyer is a Hematologist practicing medicine in Palo Alto, California. He has been practicing medicine for over 18 years.

Dr. Meyer is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Islet Cell Transplantation.

He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 8 clinical trials.

Graduate Year

2008

Specialties

Hematology

Licenses

Internal Medicine in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Stanford Hospital and Clinics
965 High St, Palo Alto, CA 94301
Other Locations
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
Intervention Type: Drug, Device
Study Phase: Phase 1
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Enrollment Status: Completed
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, CD22 CAR
Study Phase: Phase 1
Bone Marrow Grafting for Leukemia and Lymphoma
Bone Marrow Grafting for Leukemia and Lymphoma
Enrollment Status: Enrolling_by_invitation
Publish Date: December 18, 2025
Intervention Type: Procedure
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
Study Phase: Phase 1
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Biological, Procedure
Study Drugs: Purified T Cells, Purified Regulatory T Cells
Study Phase: Phase 1/Phase 2
A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Biological
Study Phase: Phase 1
Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders
Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders
Enrollment Status: Completed
Publish Date: May 07, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: March 30, 2017
Intervention Type: Biological
Study Phase: Phase 1
View 7 Less Clinical Trials

98 Total Publications

CD38 defines a therapeutically targetable pathogenic T cell population for precision immunotherapy in autoimmune diabetes.
CD38 defines a therapeutically targetable pathogenic T cell population for precision immunotherapy in autoimmune diabetes.
Journal: bioRxiv : the preprint server for biology
Published: July 10, 2026
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (1.1 miles away)
650-498-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Gotlib is a Hematologist practicing medicine in Palo Alto, California. Dr. Gotlib is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Gotlib is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (1.1 miles away)
650-723-0822
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Miklos is a Hematologist practicing medicine in Stanford, California. Dr. Miklos is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michaela Liedtke is a Hematologist practicing medicine in Palo Alto, California. Dr. Liedtke is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Everett H. Meyer

How do I make an appointment with Dr. Everett H. Meyer?

You can book an appointment with Dr. Everett H. Meyer by calling their office at 650-723-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Everett H. Meyer a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Everett H. Meyer is classified as an Elite expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Everett H. Meyer specialize in?

While Dr. Everett H. Meyer is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Everett H. Meyer participate in research or clinical trials?

Yes. Dr. Everett H. Meyer has published 98 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Everett H. Meyer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Everett H. Meyer accept my insurance?

Dr. Everett H. Meyer accepts most major insurance plans, including Aetna and Change Healthcare. We recommend calling the office directly at 650-723-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meyer's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile